A new class of protein cancer biomarker candidates: Differentially expressed splice variants of ERBB2 (HER2/neu) and ERBB1 (EGFR) in breast cancer cell lines

Journal of Proteomics

Volumn 107, Issue , 2014, Pages 103-112

  Omenn, Gilbert S ^a   Guan, Yuanfang ^a   Menon, Rajasree ^a  

^a UNIVERSITY OF MICHIGAN   (United States)

Author keywords

Breast cancer subtypes; ERBB1 (EGFR); ERBB2 (HER2 neu); Pathway analyses; Splice variant proteins; Splice variant transcripts

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EGFR PROTEIN, HUMAN; ERBB2 PROTEIN, HUMAN; ISOPROTEIN; TUMOR MARKER;

ALTERNATIVE RNA SPLICING; BREAST CANCER; BREAST CANCER CELL LINE; GENE EXPRESSION; GENE ONTOLOGY; HUMAN; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; PROTEIN PROTEIN INTERACTION; REVIEW; RNA SPLICING; TREATMENT RESPONSE; BIOSYNTHESIS; BREAST TUMOR; FEMALE; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; TUMOR CELL LINE;

ALTERNATIVE SPLICING; BREAST NEOPLASMS; CELL LINE, TUMOR; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; PROTEIN ISOFORMS; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, ERBB-2; TUMOR MARKERS, BIOLOGICAL;

EID: 84904434702     PISSN: 18743919     EISSN: 18767737     Source Type: Journal    
DOI: 10.1016/j.jprot.2014.04.012     Document Type: Review

References (41)

1. Zhang J., Manley J.L. Misregulation of pre-mRNA alternative splicing in cancer. Cancer Discov 2013, 3:1228-1237.
2. Paik Y.K., Omenn G.S., Thongboonkerd V., Marko-Varga G., Hancock W.S. Genome-wide proteomics, Chromosome-centric Human Proteome Project (C-HPP), part II. J Proteome Res 2014, 13:1-4.
3. Lane L., Bairoch A., Beavis R.C., Deutsch E.W., Gaudet P., Lundberg E., et al. Metrics for the Human Proteome Project 2013-2014 and strategies for finding missing proteins. J Proteome Res 2014, 13:15-20.
4. Omenn G.S., Menon R., Zhang Y. Innovations in proteomic profiling of cancers: alternative splice variants as a new class of cancer biomarker candidates and bridging of proteomics with structural biology. J Proteomics 2013, 90:28-37.
5. Omenn G.S. Plasma proteomics, the Human Proteome Project, and cancer-associated alternative splice variant proteins. Biochim Biophys Acta 2013, 10.1016/j.bbapap.2013.10.016.
6. Legrain P., Aebersold R., Archakov A., Bairoch A., Bala K., Beretta L., et al. The human proteome project: current state and future direction. Mol Cell Proteomics 2011, 10. [M111 009993].
7. Paik Y.K., Jeong S.K., Omenn G.S., Uhlen M., Hanash S., Cho S.Y., et al. The Chromosome-Centric Human Proteome Project for cataloging proteins encoded in the genome. Nat Biotechnol 2012, 30:221-223.
8. Marko-Varga G., Omenn G.S., Paik Y.K., Hancock W.S. A first step toward completion of a genome-wide characterization of the human proteome. J Proteome Res 2013, 12:1-5.
9. Liu S., Im H., Bairoch A., Cristofanilli M., Chen R., Deutsch E.W., et al. A chromosome-centric human proteome project (C-HPP) to characterize the sets of proteins encoded in chromosome 17. J Proteome Res 2013, 12:45-57.
10. Zhang E.Y., Cristofanilli M., Robertson F., Reuben J.M., Mu Z., Beavis R.C., et al. Genome wide proteomics of ERBB2 and EGFR and other oncogenic pathways in inflammatory breast cancer. J Proteome Res 2013, 12:2805-2817.
11. Menon R., Im H., Zhang E.Y., Wu S.L., Chen R., Snyder M., et al. Distinct splice variants and pathway enrichment in the cell-line models of aggressive human breast cancer subtypes. J Proteome Res 2014, 13:212-227.
12. Menon R., Omenn G.S. Proteomic characterization of novel alternative splice variant proteins in human epidermal growth factor receptor 2/neu-induced breast cancers. Cancer Res 2010, 70:3440-3449.
13. Dressman M.A., Baras A., Malinowski R., Alvis L.B., Kwon I., Walz T.M., et al. Gene expression profiling detects gene amplification and differentiates tumor types in breast cancer. Cancer Res 2003, 63:2194-2199.
14. Whiteaker J.R., Zhang H., Zhao L., Wang P., Kelly-Spratt K.S., Ivey R.G., et al. Integrated pipeline for mass spectrometry-based discovery and confirmation of biomarkers demonstrated in a mouse model of breast cancer. J Proteome Res 2007, 6:3962-3975.
15. Menon R., Zhang Q., Zhang Y., Fermin D., Bardeesy N., DePinho R.A., et al. Identification of novel alternative splice isoforms of circulating proteins in a mouse model of human pancreatic cancer. Cancer Res 2009, 69:300-309.
16. Katz E., Dubois-Marshall S., Sims A.H., Faratian D., Li J., Smith E.S., et al. A gene on the HER2 amplicon, C35, is an oncogene in breast cancer whose actions are prevented by inhibition of Syk. Br J Cancer 2010, 103:401-410.
17. Grunewald T.G., Kammerer U., Kapp M., Eck M., Dietl J., Butt E., et al. Nuclear localization and cytosolic overexpression of LASP-1 correlates with tumor size and nodal-positivity of human breast carcinoma. BMC Cancer 2007, 7:198.
18. Fagerberg L., Oksvold P., Skogs M., Algenas C., Lundberg E., Ponten F., et al. Contribution of antibody-based protein profiling to the Human Chromosome-centric Proteome Project (C-HPP). J Proteome Res 2013, 12:2439-2448.
19. Cox J., Mann M. 1D and 2D annotation enrichment: a statistical method integrating quantitative proteomics with complementary high-throughput data. BMC Bioinformatics 2012, 13(Suppl. 16):S12.
20. Holbro T., Beerli R.R., Maurer F., Koziczak M., Barbas C.F., Hynes N.E. The ErbB2/ErbB3 heterodimer functions as an oncogenic unit: ErbB2 requires ErbB3 to drive breast tumor cell proliferation. Proc Natl Acad Sci U S A 2003, 100:8933-8938.
21. Menon R., Roy A., Mukherjee S., Belkin S., Zhang Y., Omenn G.S. Functional implications of structural predictions for alternative splice proteins expressed in Her2/neu-induced breast cancers. J Proteome Res 2011, 10:5503-5511.
22. Jin Q., Yuan L.X., Boulbes D., Baek J.M., Wang Y.N., Gomez-Cabello D., et al. Fatty acid synthase phosphorylation: a novel therapeutic target in HER2-overexpressing breast cancer cells. Breast Cancer Res 2010, 12:1-18.
23. Kumar-Sinha C., Ignatoski K.W., Lippman M.E., Ethier S.P., Chinnaiyan A.M. Transcriptome analysis of HER2 reveals a molecular connection to fatty acid synthesis. Cancer Res 2003, 63:132-139.
24. Houchens N.W., Merajver S.D. Molecular determinants of the inflammatory breast cancer phenotype. Oncology 2008, 22:1556-1561. [discussion 61, 65-8, 76].
25. Wu M., Wu Z.F., Rosenthal D.T., Rhee E.M., Merajver S.D. Characterization of the roles of RHOC and RHOA GTPases in invasion, motility, and matrix adhesion in inflammatory and aggressive breast cancers. Cancer 2010, 116:2768-2782.
26. Eksi R., Li H.D., Menon R., Wen Y., Omenn G.S., Kretzler M., et al. Systematically differentiating functions for alternatively spliced isoforms through integrating RNA-seq data. PLoS Comput Biol 2013, 9:e1003314.
27. Oberwinkler J., Lis A., Giehl K.M., Flockerzi V., Philipp S.E. Alternative splicing switches the divalent cation selectivity of TRPM3 channels. J Biol Chem 2005, 280:22540-22548.
28. Revil T., Toutant J., Shkreta L., Garneau D., Cloutier P., Chabot B. Protein kinase C-dependent control of Bcl-x alternative splicing. Mol Cell Biol 2007, 27:8431-8441.
29. Vegran F., Boidot R., Oudin C., Riedinger J.M., Bonnetain F., Lizard-Nacol S. Overexpression of caspase-3s splice variant in locally advanced breast carcinoma is associated with poor response to neoadjuvant chemotherapy. Clin Cancer Res 2006, 12:5794-5800.
30. Pan Q., Shai O., Lee L.J., Frey B.J., Blencowe B.J. Deep surveying of alternative splicing complexity in the human transcriptome by high-throughput sequencing. Nat Genet 2008, 40:1413-1415.
31. Chung S.S., Giehl N., Wu Y., Vadgama J.V. STAT3 activation in HER2-overexpressing breast cancer promotes epithelial-mesenchymal transition and cancer stem cell traits. Int J Oncol 2014, 44:403-411.
32. Baron A.T., Cora E.M., Lafky J.M., Boardman C.H., Buenafe M.C., Rademaker A., et al. Soluble epidermal growth factor receptor (sEGFR/sErbB1) as a potential risk, screening, and diagnostic serum biomarker of epithelial ovarian cancer. Cancer Epidemiol Biomarkers Prev 2003, 12:103-113.
33. Wilken J.A., Baron A.T., Maihle N.J. The epidermal growth factor receptor conundrum. Cancer 2010, 117:2358-2360.
34. Center for Cancer Research Our Science - Ried Website [Updated December 18, 2013. Accessed March 06, 2014]. http://ccr.cancer.gov/staff/staff.asp?profileid=5680.
35. Misteli T. Beyond the sequence: cellular organization of genome function. Cell 2007, 128:787-800.
36. Roukos V., Voss T.C., Schmidt C.K., Lee S., Wangsa D., Misteli T. Spatial dynamics of chromosome translocations in living cells. Science 2013, 341:660-664.
37. Yoshida K., Sanada M., Shiraishi Y., Nowak D., Nagata Y., Yamamoto R., et al. Frequent pathway mutations of splicing machinery in myelodysplasia. Nature 2011, 478:64-69.
38. Barbosa-Morais N.L., Irimia M., Pan Q., Xiong H.Y., Gueroussov S., Lee L.J., et al. The evolutionary landscape of alternative splicing in vertebrate species. Science 2012, 338:1587-1593.
39. Merkin J., Russell C., Chen P., Burge C.B. Evolutionary dynamics of gene and isoform regulation in Mammalian tissues. Science 2012, 338:1593-1599.
40. Kaida D., Motoyoshi H., Tashiro E., Nojima T., Hagiwara M., Ishigami K., et al. Spliceostatin A targets SF3b and inhibits both splicing and nuclear retention of pre-mRNA. Nat Chem Biol 2007, 3:576-583.
41. Papasaikas P., Valcarcel J. Evolution. Splicing in 4D. Science 2012, 338:1547-1548.